Join

Compare · BHG vs ILMN

BHG vs ILMN

Side-by-side comparison of Bright Health Group Inc. (BHG) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BHG and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
  • ILMN is the larger of the two at $23.91B, about 14.3x BHG ($1.67B).
  • ILMN has hit the wire 22 times in the past 4 weeks while BHG has been quiet.
  • Both have 25 recent analyst ratings on file.
MetricBHGILMN
Company
Bright Health Group Inc.
Illumina Inc.
Price
$14.94+43.65%
$158.13-2.55%
Market cap
$1.67B
$23.91B
1M return
-
+14.02%
1Y return
-
+86.08%
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2021
2000
News (4w)
0
22
Recent ratings
25
25
BHG

Bright Health Group Inc.

Bright Health Group, Inc., an integrated care delivery company, engages in the delivery and financing of health insurance plans in the United States. It operates in two segments, NeueHealth and Bright HealthCare. The company offers individual and family, Medicare, and employers insurance plans. It also operates 28 managed and affiliated risk-bearing primary care clinics. The company was formerly known as Bright Health Inc. and changed its name to Bright Health Group, Inc. in February 2021. Bright Health Group, Inc. was incorporated in 2015 and is based in Minneapolis, Minnesota.

ILMN

Illumina Inc.

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.

Latest BHG

Latest ILMN